Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells
Metrics: PDF 629 views | HTML 1215 views | ?
Jialiang Wang1,*, Yifan Lian1,*, Yurong Gu1,2,*, Hongbo Wang1, Lin Gu1, Yanlin Huang2, Liang Zhou2 and Yuehua Huang1,2
1Guangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
2Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
*These authors contributed equally to this work
Yuehua Huang, email: firstname.lastname@example.org
Keywords: lonafarnib; hepatocellular carcinoma; synergistic effect; chemoresistance
Received: April 21, 2017 Accepted: October 12, 2017 Published: October 26, 2017
Hepatocellular carcinoma (HCC) is a common and deadly cancer worldwide and is often refractory to chemotherapy due to the development of multidrug resistance. Lonafarnib is an orally active and potent non-peptidomimetic inhibitor of farnesyl transferase. Here, using in vitro HCC cell models, we demonstrated that lonafarnib inhibited tumor proliferation and reduced the activity of mitogen-activated protein kinases pathways. In addition, lonafarnib caused G1 to S phase arrest through the downregulation of Cyclin D1, CDK6 and SKP2, while it induced cellular apoptosis by promoting the cleavage and activation of Caspase-3 and PARP. When combined with doxorubicin and sorafenib, lonafarnib was able to increase the sensitivity of HCC cells to chemotherapy. Furthermore, we also constructed ABCB1-overexpressing HCC cells and found that lonafarnib decreased chemoresistance by inhibiting ABCB1-mediated drug efflux activity. These results suggest that lonafarnib may be a promising synergistic agent for improving the treatment of drug-resistant HCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.